A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Trial details
- Registry ID
- NCT05725018
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as pz-cel
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsNCT05725018 | ABEO | Phase 3 | Active not recruiting | 2025-09-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |